OncoGenex Provides Update On 3 SYNERGY Trial - Quick Facts

(RTTNews) - OncoGenex Pharmaceuticals, Inc. (OGXI) announced the pre-specified number of events required for final analysis of the Phase 3 SYNERGY trial has been reached. There have been 1,022 men enrolled into SYNERGY at 148 cancer centers throughout North America, Europe, Israel and South Korea. SYNERGY completed enrollment in 2012 and final survival results are expected to be announced by mid-2014.

The primary efficacy endpoint of SYNERGY will analyze overall survival benefit for custirsen in combination with standard first-line docetaxel chemotherapy and prednisone in men with metastatic castrate-resistant prostate cancer. Overall survival results will remain blinded until all study data have been thoroughly reviewed and prepared for final analysis.